Literature DB >> 27062563

Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Zhen Ren1, Horia Pribiag2, Sarah J Jefferson1, Matthew Shorey1, Thomas Fuchs1, David Stellwagen2, Bernhard Luscher3.   

Abstract

BACKGROUND: Major depressive disorder is increasingly recognized to involve functional deficits in both gamma-aminobutyric acid (GABA)ergic and glutamatergic synaptic transmission. To elucidate the relationship between these phenotypes, we used GABAA receptor γ2 subunit heterozygous (γ2(+/-)) mice, which we previously characterized as a model animal with construct, face, and predictive validity for major depressive disorder.
METHODS: To assess possible consequences of GABAergic deficits on glutamatergic transmission, we quantitated the cell surface expression of N-methyl-D-aspartate (NMDA)-type and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors and the function of synapses in the hippocampus and medial prefrontal cortex of γ2(+/-) mice. We also analyzed the effects of an acute dose of the experimental antidepressant ketamine on all these parameters in γ2(+/-) versus wild-type mice.
RESULTS: Modest defects in GABAergic synaptic transmission of γ2(+/-) mice resulted in a strikingly prominent homeostatic-like reduction in the cell surface expression of NMDA-type and AMPA-type glutamate receptors, along with prominent functional impairment of glutamatergic synapses in the hippocampus and medial prefrontal cortex. A single subanesthetic dose of ketamine normalized glutamate receptor expression and synaptic function of γ2(+/-) mice to wild-type levels for a prolonged period, along with antidepressant-like behavioral consequences selectively in γ2(+/-) mice. The GABAergic synapses of γ2(+/-) mice were potentiated by ketamine in parallel but only in the medial prefrontal cortex.
CONCLUSIONS: Depressive-like brain states that are caused by GABAergic deficits involve a homeostatic-like reduction of glutamatergic transmission that is reversible by an acute, subanesthetic dose of ketamine, along with regionally selective potentiation of GABAergic synapses. The data merge the GABAergic and glutamatergic deficit hypotheses of major depressive disorder.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant drug mechanisms; GABA; Glutamate; Homeostatic synaptic plasticity; Major depressive disorder; Neuroligin

Mesh:

Substances:

Year:  2016        PMID: 27062563      PMCID: PMC4983262          DOI: 10.1016/j.biopsych.2016.02.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  71 in total

1.  The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses.

Authors:  Claude Schweizer; Sylvia Balsiger; Horst Bluethmann; Isabelle M Mansuy; Jean-Marc Fritschy; Hanns Mohler; Bernhard Lüscher
Journal:  Mol Cell Neurosci       Date:  2003-10       Impact factor: 4.314

2.  Depressive mood modulates the anterior lateral CA1 and DG/CA3 during a pattern separation task in cognitively intact individuals: a functional MRI study.

Authors:  Takeshi Fujii; Daisuke N Saito; Hisakazu T Yanaka; Hirotaka Kosaka; Hidehiko Okazawa
Journal:  Hippocampus       Date:  2013-11-12       Impact factor: 3.899

Review 3.  Neurogenesis and affective disorders.

Authors:  Benjamin A Samuels; René Hen
Journal:  Eur J Neurosci       Date:  2011-03       Impact factor: 3.386

4.  Effect of antidepressant drugs on the vmPFC-limbic circuitry.

Authors:  Celene H Chang; Michael C Chen; Jun Lu
Journal:  Neuropharmacology       Date:  2015-01-28       Impact factor: 5.250

5.  Pattern separation of emotional information in hippocampal dentate and CA3.

Authors:  Stephanie L Leal; Sarah K Tighe; Craig K Jones; Michael A Yassa
Journal:  Hippocampus       Date:  2014-05-30       Impact factor: 3.899

6.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

7.  Increased levels of glutamate in brains from patients with mood disorders.

Authors:  Kenji Hashimoto; Akira Sawa; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2007-06-15       Impact factor: 13.382

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  The ability of BDNF to modify neurogenesis and depressive-like behaviors is dependent upon phosphorylation of tyrosine residues 365/367 in the GABA(A)-receptor γ2 subunit.

Authors:  Mansi Vithlani; Rochelle M Hines; Ping Zhong; Miho Terunuma; Dustin J Hines; Raquel Revilla-Sanchez; Rachel Jurd; Phillip Haydon; Maribel Rios; Nicholas Brandon; Zhen Yan; Stephen J Moss
Journal:  J Neurosci       Date:  2013-09-25       Impact factor: 6.167

10.  Deficits in phosphorylation of GABA(A) receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus.

Authors:  Miho Terunuma; Jianwei Xu; Mansi Vithlani; Werner Sieghart; Josef Kittler; Menelas Pangalos; Philip G Haydon; Douglas A Coulter; Stephen J Moss
Journal:  J Neurosci       Date:  2008-01-09       Impact factor: 6.167

View more
  33 in total

Review 1.  Neuropathology of suicide: recent findings and future directions.

Authors:  P-E Lutz; N Mechawar; G Turecki
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

2.  Somatostatin-positive GABAergic interneuron: new targets for depression.

Authors:  C Zhang; X Liu; T-F Yuan
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

3.  Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.

Authors:  Jessica R Gilbert; Elizabeth D Ballard; Christina S Galiano; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-03

Review 4.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

Review 5.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

6.  Dissociation of Golgi-associated DHHC-type Zinc Finger Protein (GODZ)- and Sertoli Cell Gene with a Zinc Finger Domain-β (SERZ-β)-mediated Palmitoylation by Loss of Function Analyses in Knock-out Mice.

Authors:  Casey L Kilpatrick; Shoko Murakami; Mengyang Feng; Xia Wu; Rachnanjali Lal; Gong Chen; Keyong Du; Bernhard Luscher
Journal:  J Biol Chem       Date:  2016-11-14       Impact factor: 5.157

Review 7.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

8.  Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine.

Authors:  Mengyang Feng; Nicole A Crowley; Akshilkumar Patel; Yao Guo; Sierra E Bugni; Bernhard Luscher
Journal:  Neuroscience       Date:  2019-03-08       Impact factor: 3.590

Review 9.  An Emerging Circuit Pharmacology of GABAA Receptors.

Authors:  Elif Engin; Rebecca S Benham; Uwe Rudolph
Journal:  Trends Pharmacol Sci       Date:  2018-06-11       Impact factor: 14.819

10.  Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression.

Authors:  Yu-Cheng Ho; Tzer-Bin Lin; Ming-Chun Hsieh; Cheng-Yuan Lai; Dylan Chou; Yat-Pang Chau; Gin-Den Chen; Hsien-Yu Peng
Journal:  Neuropsychopharmacology       Date:  2017-08-30       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.